Epidemiologic data of hyperuricaemia prevalence in the conditions of primary care in Slovakia

Česká verzia

Authors: Andrej Dukát ¹; Peter Sabaka ¹; Ján Gajdošík ²; Marjan Vrbnjak ¹; Oliver Tlčimuka ¹; Peter Gavorník ¹; Ľudovít Gašpar ¹; F. Šimko ³
Authors place of work: II. interná klinika LF UK a UN Bratislava, Slovenská republika, prednosta doc. MUDr. Ľudovít Gašpar, CSc. ¹; Neštátna ambulancia pre dospelých Nové Zámky, Slovenská republika, riaditeľ prof. MUDr. Ján Gajdošík, CSc. ²; III. interná klinika LF UK a UN Bratislava, Slovenská republika, prednosta doc. MUDr. Viliam Mojto, CSc. ³
Published in the journal: Vnitř Lék 2015; 61(Suppl 5): 7-11
Category: Original Contributions

Summary

Hyperuricaemia represents nowaday the new risk factor for cardiovascular diseases. Prevalence data and its treatment in our patient´s population are still missing. Literature data shows, that its prevalence differs in various populations significantly from 4 % up to 40 % with race and geographical means. In the hospital population its prevalence is about 7 % and represents the important predictor of hospital mortality, e.i with heart failure. From the Framingham data relative risk was estimated of 25 % for cardiovascular diseases, coronary heart disease and all-course mortality. From the epidemiologic survey Mirror Slovakia hyperuricaemia was evaluated from the sample of 20 000 patients from the primare care physicians in order to see the picture on this newer risk factor.

Key words:
cardiovascular diseases – epidemiology – hyperuricaemia – therapy

Zdroje

1. Alderman MH. Podagra, uric acid, and cardiovascular disease. Circulation 2007; 116(8): 880–883.

2. Culleton BF, Larson MG, Kannel WB et al. Serum uric acid and risk for cardiovascular disease and death. Ann Intern Med 1999; 131(1): 7–13.

3. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthr Res Ther 2006; 8(Suppl 1): S2.

4. Ghei M, Mihailescu M, Levinson D. Pathogenesis of hyperuricemia-recent advances. Curr Rheumatol Rep 2002; 4(3): 270–274.

5. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116(8): 894–900.

6. Feig DI, Kang DG, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359(17): 1811–1821. Erratum in N Engl J Med 2010 Jun 10; 362(23):2235.

7. Kriška M (ed). Zlyhanie farmakoterapie, možnosti prevencie. SAP; Bratislava 2015. ISBN 978–80–8960733–4.

8. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 2011; 63(10): 3136–3141.

9. Whelton A. Hyperuricemia and hypertension. Editorial comment. Hypertension 2012; 60(3): 1112–1113.

10. Špinar J, Vítovec J, Pařenica J. Hypertenze a hyperurikemie. Vnitř Lék 2005; 51(1): 82–86.

11. Loeffler LF, Navas-Acien A, Brady TM et al. Uric acid level and elevated blood pressure in US adolescents: National Health and Nutrition Examination Survey, 1999–2006. Hypertension 2012; 59(4): 811–817.

12. Tangri N, Weiner DE. Uric acid, CKD, and cardiovascular disease: confounders, culprits and circles. Am J Kidn Dis 2010; 56(2): 247–250.

13. Málek F, Ošťádal P, Pařenica J et al. Uric acid, allopuinol therapy, and mortality in patients with acute heart failure – results of the Acute Heart Failure Database registry. J Crit Care 2012; 27(6): 737. e11–24. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcrc.2012.03.011>.

14. Linhart A, Rob D. Význam kyseliny močové a terapie alopurinolem v ovlivnění kardiovaskulárních onemocnění. Vnitř Lék 2015; 61(5): 421–430.

15. Choi HK, Curhan G. Independent Impact of Gout on Mortality and Risk for Coronary Heart Disease. Circulation 2007; 116(8): 894–900.

16. Keenan T, Blaha MJ, Nasir K et al. Relation of uric acid to serum levels of high-sensitivity CRP, triglycerides, and HDL-C to hepatic stenosis. Am J Cardiol 2012; 110(12): 1787–1792.

17. Choi HK, Soriano LC, Zhang Y et al. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 2012; 344:d8190. Dostupné z DOI: <http://doi: 10.1136/bmj.d8190>.